Accenture and Philips Announce Proof of Concept App

PhilipsRoyal Philips (NYSE: PHG; AEX: PHIA) and Accenture (NYSE: ACN) have developed proof of concept software connecting a wearable display to Emotiv Insight Brainware that could ultimately give more independence to patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Affecting more than 400,000 people per year*, ALS, also known as Lou Gehrig's Disease, impairs brain and spinal cord nerve cells, gradually diminishing voluntary muscle action. Late-stage patients often become totally paralyzed while retaining brain functions.

"This proof of concept exemplifies how people, devices, data and technology could be brought together quickly to connect beyond the hospital walls in a way that can potentially help improve the quality of life for patients, wherever they are in their journey," said Jeroen Tas, CEO, Healthcare Informatics Solutions and Services for Philips. "Philips will continue to collaborate with innovative technology companies such as Accenture to explore new wearable and sensor solutions that change peoples’ lives and create a healthier future."

How it works
When a wearable display and the Emotiv Insight Brainware, which scans EEG brainwaves, are connected to a tablet, users can issue brain commands to control Philips products including Philips Lifeline Medical Alert Service, Philips SmartTV (with TP Vision), and Philips Hue personal wireless lighting. The tablet also allows control of these products using eye and voice commands. In both cases, a person could communicate preconfigured messages, request medical assistance, and control TVs and lights. Accenture and Philips developed the software that enables the integration and interaction between these multiple technologies.

The proof of concept application demonstrates how existing technology could be used to transform the quality of life for ALS patients. When patients lose muscle control and eye tracking ability, they can still potentially operate the Philips suite of connected products in their home environment through brain commands. The Emotiv technology uses sensors to tune in to electric signals produced by the wearer's brain to detect, in real-time, their thoughts, feelings and expressions. The wearable display provides visual feedback that allows the wearer to navigate through the application menu.

The Accenture Technology Labs in San Jose, California collaborated with the Philips Digital Accelerator Lab in the Netherlands to create the software to interact with the Emotiv Insight Brainware and the wearable display. Fjord, a design consultancy owned by Accenture Interactive, designed the display’s user interface.

"This proof of concept shows the potential of wearable technology in a powerful new way - helping people with serious diseases and mobility issues take back some control of their lives through digital innovation," said Paul Daugherty, Accenture's chief technology officer. "It is another demonstration of how Accenture and Philips, collaborating with other technology innovators, seek to improve the lives of people with healthcare challenges."

"Empowering people with Lou Gehrig's disease to live fuller lives is at the heart of the ALS Association's mission," said Ineke Zaal, spokesperson for Stichting ALS in The Netherlands. "We are tremendously excited about the potential for this proof of concept to give people with ALS greater independence and quality of life as we continue to actively search for a cure."

For more information on the proof of concept application for controlling Philips connected technologies with brain commands, visit http://www.philips.com/braincommand

*Source: International Alliance of ALS/MND Associations

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 113,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About Accenture
Accenture is a global management consulting, technology services and outsourcing company, with more than 293,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$28.6 billion for the fiscal year ended Aug. 31, 2013.

About Emotiv
Emotiv is a bioinformatics company offering a unique platform for crowd-sourced brain research. Emotiv leverages cloud computing, big data and mobile technology to offer valuable personal insights and accelerate brain research globally.

Most Popular Now

ChatGPT can Produce Medical Record Notes…

The AI model ChatGPT can write administrative medical notes up to ten times faster than doctors without compromising quality. This is according to a new study conducted by researchers at...

Alcidion and Novari Health Forge Strateg…

Alcidion Group Limited, a leading provider of FHIR-native patient flow solutions for healthcare, and Novari Health, a market leader in waitlist management and referral management technologies, have joined forces to...

Greater Manchester Reaches New Milestone…

Radiologists and radiographers at Northern Care Alliance NHS Foundation Trust have become the first in Greater Manchester to use the Sectra picture archiving and communication system (PACS) to report on...

Can Language Models Read the Genome? Thi…

The same class of artificial intelligence that made headlines coding software and passing the bar exam has learned to read a different kind of text - the genetic code. That code...

Study Shows Human Medical Professionals …

When looking for medical information, people can use web search engines or large language models (LLMs) like ChatGPT-4 or Google Bard. However, these artificial intelligence (AI) tools have their limitations...

Advancing Drug Discovery with AI: Introd…

A transformative study published in Health Data Science, a Science Partner Journal, introduces a groundbreaking end-to-end deep learning framework, known as Knowledge-Empowered Drug Discovery (KEDD), aimed at revolutionizing the field...

Bayer and Google Cloud to Accelerate Dev…

Bayer and Google Cloud announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will...

Shared Digital NHS Prescribing Record co…

Implementing a single shared digital prescribing record across the NHS in England could avoid nearly 1 million drug errors every year, stopping up to 16,000 fewer patients from being harmed...

Ask Chat GPT about Your Radiation Oncolo…

Cancer patients about to undergo radiation oncology treatment have lots of questions. Could ChatGPT be the best way to get answers? A new Northwestern Medicine study tested a specially designed ChatGPT...

Wanted: Young Talents. DMEA Sparks Bring…

9 - 11 April 2024, Berlin, Germany. The digital health industry urgently needs skilled workers, which is why DMEA sparks focuses on careers, jobs and supporting young people. Against the backdrop of...

North West Anglia Works with Clinisys to…

North West Anglia NHS Foundation Trust has replaced two, legacy laboratory information systems with a single instance of Clinisys WinPath. The trust, which serves a catchment of 800,000 patients in North...

Can AI Techniques Help Clinicians Assess…

Investigators have applied artificial intelligence (AI) techniques to gait analyses and medical records data to provide insights about individuals with leg fractures and aspects of their recovery. The study, published in...